Most Read

In July this year, the company revealed a potential two-pronged strategy for the treatment of Covid-19. First, preclinical cell culture experiments shown CRV431 reduced SARS-CoV-1 production of infectious

The deal, which covers commercial, clinical and research-stage oncology portfolio, consists of an upfront payment of $1.8bn. Agios is also eligible to secure up to $200m in regulatory

As per the EUA, the mRNA-1273 vaccine can be administered to individuals aged 18 years or older. Following the EUA, Moderna has commenced delivery of the Covid-19 vaccine

Lupus nephritis, an inflammation of the kidneys caused by systemic lupus erythematosus (SLE), may lead to end-stage kidney disease. Benlysta, a BLyS-specific inhibitor, is a human monoclonal antibody

Based in Cambridge of Massachusetts, Cadent Therapeutics is involved in the development of therapies to treat cognitive, mood, and movement disorders. Cadent will secure a $210m upfront payment,

The randomised, controlled and double-blind study will recruit 352 patients in between 25 and 30 medical centres and hospitals in North America. The multicentre study will evaluate the

PAH is a rare and chronic progressing disorder characterised by the narrowing of small pulmonary arteries and inflated blood pressure in the pulmonary circulation. Sotatercept, an investigational reverse-remodelling

Via newly established Swedish limited liability company Roar BidCo AB, EQT IX has announced a public offer of SEK220 ($26.1) in cash per share to the shareholders of

Leqvio, a first-in-class small interfering RNA (siRNA), has been approved based on data from the ORION clinical development programme. The approval allows to use Leqvio in combination with